| Product Code: ETC7553816 | Publication Date: Sep 2024 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The India small cell lung cancer therapeutics market import shipment demonstrated a steady expansion from 2020 to 2024, with a notable CAGR of 3.0% over the period. The growth rate notably spiked by 26.5% between 2023 and 2024, indicating a surge in market momentum and a positive overall trend.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 India Small Cell Lung Cancer (SCLC) Therapeutics Market Overview |
3.1 India Country Macro Economic Indicators |
3.2 India Small Cell Lung Cancer (SCLC) Therapeutics Market Revenues & Volume, 2021 & 2031F |
3.3 India Small Cell Lung Cancer (SCLC) Therapeutics Market - Industry Life Cycle |
3.4 India Small Cell Lung Cancer (SCLC) Therapeutics Market - Porter's Five Forces |
3.5 India Small Cell Lung Cancer (SCLC) Therapeutics Market Revenues & Volume Share, By Therapy Type, 2021 & 2031F |
3.6 India Small Cell Lung Cancer (SCLC) Therapeutics Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.7 India Small Cell Lung Cancer (SCLC) Therapeutics Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 India Small Cell Lung Cancer (SCLC) Therapeutics Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 India Small Cell Lung Cancer (SCLC) Therapeutics Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of small cell lung cancer (SCLC) in India |
4.2.2 Growing awareness about early detection and treatment options for SCLC |
4.2.3 Advancements in medical technology leading to more effective therapeutics for SCLC |
4.2.4 Government initiatives to improve healthcare infrastructure and access to cancer treatments in India |
4.3 Market Restraints |
4.3.1 High cost of SCLC therapeutics limiting access to treatment for some patients |
4.3.2 Limited availability of specialized healthcare facilities for SCLC treatment in certain regions of India |
4.3.3 Regulatory hurdles and lengthy approval processes for new SCLC therapeutics in the Indian market |
5 India Small Cell Lung Cancer (SCLC) Therapeutics Market Trends |
6 India Small Cell Lung Cancer (SCLC) Therapeutics Market, By Types |
6.1 India Small Cell Lung Cancer (SCLC) Therapeutics Market, By Therapy Type |
6.1.1 Overview and Analysis |
6.1.2 India Small Cell Lung Cancer (SCLC) Therapeutics Market Revenues & Volume, By Therapy Type, 2021- 2031F |
6.1.3 India Small Cell Lung Cancer (SCLC) Therapeutics Market Revenues & Volume, By Targeted Therapy, 2021- 2031F |
6.1.4 India Small Cell Lung Cancer (SCLC) Therapeutics Market Revenues & Volume, By Immunotherapy, 2021- 2031F |
6.1.5 India Small Cell Lung Cancer (SCLC) Therapeutics Market Revenues & Volume, By Chemotherapy, 2021- 2031F |
6.2 India Small Cell Lung Cancer (SCLC) Therapeutics Market, By Drug Type |
6.2.1 Overview and Analysis |
6.2.2 India Small Cell Lung Cancer (SCLC) Therapeutics Market Revenues & Volume, By Atezolizumab, 2021- 2031F |
6.2.3 India Small Cell Lung Cancer (SCLC) Therapeutics Market Revenues & Volume, By Durvalumab, 2021- 2031F |
6.2.4 India Small Cell Lung Cancer (SCLC) Therapeutics Market Revenues & Volume, By Etoposide, 2021- 2031F |
6.2.5 India Small Cell Lung Cancer (SCLC) Therapeutics Market Revenues & Volume, By Methotrexate, 2021- 2031F |
6.2.6 India Small Cell Lung Cancer (SCLC) Therapeutics Market Revenues & Volume, By Topotecan, 2021- 2031F |
6.2.7 India Small Cell Lung Cancer (SCLC) Therapeutics Market Revenues & Volume, By Others, 2021- 2031F |
6.3 India Small Cell Lung Cancer (SCLC) Therapeutics Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 India Small Cell Lung Cancer (SCLC) Therapeutics Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.3 India Small Cell Lung Cancer (SCLC) Therapeutics Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.3.4 India Small Cell Lung Cancer (SCLC) Therapeutics Market Revenues & Volume, By Others, 2021- 2031F |
6.4 India Small Cell Lung Cancer (SCLC) Therapeutics Market, By Distribution Channel |
6.4.1 Overview and Analysis |
6.4.2 India Small Cell Lung Cancer (SCLC) Therapeutics Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F |
6.4.3 India Small Cell Lung Cancer (SCLC) Therapeutics Market Revenues & Volume, By Retail Pharmacies, 2021- 2031F |
6.4.4 India Small Cell Lung Cancer (SCLC) Therapeutics Market Revenues & Volume, By Online Pharmacies, 2021- 2031F |
7 India Small Cell Lung Cancer (SCLC) Therapeutics Market Import-Export Trade Statistics |
7.1 India Small Cell Lung Cancer (SCLC) Therapeutics Market Export to Major Countries |
7.2 India Small Cell Lung Cancer (SCLC) Therapeutics Market Imports from Major Countries |
8 India Small Cell Lung Cancer (SCLC) Therapeutics Market Key Performance Indicators |
8.1 Survival rates of SCLC patients in India |
8.2 Adoption rates of new SCLC therapeutics in the Indian market |
8.3 Number of clinical trials for SCLC treatments conducted in India |
8.4 Patient satisfaction levels with SCLC treatment options available |
9 India Small Cell Lung Cancer (SCLC) Therapeutics Market - Opportunity Assessment |
9.1 India Small Cell Lung Cancer (SCLC) Therapeutics Market Opportunity Assessment, By Therapy Type, 2021 & 2031F |
9.2 India Small Cell Lung Cancer (SCLC) Therapeutics Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.3 India Small Cell Lung Cancer (SCLC) Therapeutics Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 India Small Cell Lung Cancer (SCLC) Therapeutics Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 India Small Cell Lung Cancer (SCLC) Therapeutics Market - Competitive Landscape |
10.1 India Small Cell Lung Cancer (SCLC) Therapeutics Market Revenue Share, By Companies, 2024 |
10.2 India Small Cell Lung Cancer (SCLC) Therapeutics Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |